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PCSK9 inhibitors for hypercholesterolaemia
New drugs, old problems
Patricia McGettigan reader in clinical pharmacology and medical education 1, Robin E Ferner director 2
1William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, UK; 2West Midlands Centre for Adverse Drug
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Statins (hydroxymethyl-glutaryl coenzyme A reductase
inhibitors) reduce “bad” low density lipoprotein (LDL)
cholesterol concentrations and cardiovascular risk. So too, do
better diet and more exercise, which together almost halve rates
of coronary event rates when compared with an “unfavourable
lifestyle.”3 For some people, though, statins and other medicines
cause unacceptable adverse effects or are inadequate to control
LDL cholesterol even when combined with lifestyle changes.4 5
People with familial hypercholesterolaemia have particularly
high concentrations of LDL cholesterol, and a new generation
of drugs promises to help control this.
The drugs derived from the discovery that a few people with
very low LDL cholesterol concentrations have gene mutations
that cause loss of function of the enzyme PCSK9 (proprotein
convertase-subtilisin/kexin type 9).6 7 LDL receptors on the
surface of hepatocytes bind circulating LDL cholesterol and are
then endocytosed. Within the cell, receptors are either recycled
or degraded. We now know that PCSK9 switches this process
towards degradation, and if PCSK9 is inhibited, more LDL
receptors are recycled to the cell surface, where they can take
up more LDL cholesterol.
This mechanistic insight has led to two newly licensed PCSK9
inhibitors, alirocumab and evolocumab. Both drugs are
monoclonal antibodies, given by subcutaneous injection every
two to four weeks. They significantly reduce LDL cholesterol
concentrations compared with placebo, whether used alone or
added to standard therapy.8-11 Average concentration fell about
60% from around 3.15 mmol/L (120 mg/L) at baseline to around
1.3 mmol/L (50 mg/L) in two large, industry sponsored trials
lasting up to 78 weeks. Most trial participants were already
taking statins and a few were taking ezetimibe or other drugs
(see supplementary table on bmj.com) 10 11
The primary outcome in the alirocumab study was change in
LDL cholesterol concentration from baseline.11 This was a
secondary outcome in the evolocumab study, in which adverse
events were the primary outcome.10 Since this was an open label
extension of 12 earlier studies, however, participants were
already known to tolerate evolocumab.
The National Institute for Health and Care Excellence
recommends the new drugs for primary and secondary
prevention in people with primary heterozygous familial
hypercholesterolaemia whose LDL cholesterol concentrations
are persistently above 5.0 mmol/L (primary prevention) or 3.5
mmol/L (secondary prevention).8 9 In non-familial
hypercholesterolaemia or mixed dyslipidaemia the drugs are
recommended only as secondary prevention for patients with a
high or very high risk of cardiovascular disease and LDL
cholesterol concentrations above defined thresholds after the
maximum dose of other drugs has been reached or when further
titration is limited by intolerance.8 9
Clinical questions
The reductions in LDL cholesterol are impressive, but there are
important gaps in our knowledge. Firstly, we cannot be sure
that reductions in LDL cholesterol will be associated with better
clinical outcomes. After all, fibrates, torcetrapib, and extended
release niacin–laropiprant reduced LDL cholesterol
concentration but not overall mortality.12-15 Relevant trials of
the PCSK9 inhibitors are due to report in 2017-18.
Secondly, the people with the greatest need for LDL cholesterol
reduction are those with familial hypercholesterolaemia. In
heterozygous familial hypercholesterolaemia, which affects
about 1 in 500 of people with European heritage,1 2 LDL
cholesterol reductions of some 60% are reported.16 However,
in patients with the much rarer and more serious homozygous
form, LDL receptors are defective or absent, and the inhibitors
therefore have considerably smaller effects, and sometimes
none.17
Furthermore, treatments with PCSK9 inhibitors will require a
lifetime of injections, but we have information on fewer than
1000 patients exposed for 18 months or longer.18 19 Few patients
younger than 18 or older than 75 were included in the studies,
and pregnant women and people with type 1 diabetes, severe
renal or liver problems, hepatitis C or HIV infection were
unrepresented.
Although people with very low LDL cholesterol concentrations
because of mutations in PCSK9 have low rates of cardiovascular
disease, the long term effects of using bioengineered drugs to
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inhibit the enzyme are unknown. Both agents are immunogenic
and can cause injection site and hypersensitivity reactions. Pfizer
halted development of bococizumab, another monoclonal
PCSK9 antibody, because its immunogenicity often led to
hypersensitivity reactions and loss of efficacy.20
Neuropsychiatric and cognitive effects have been described but
remain uncharacterised. Other adverse effects may emerge only
with time.
The clinical trials, then, show that PCSK9 inhibitors reduce
LDL cholesterol concentration in the short term, but we are still
uncertain about the long term outcomes or the nature and
frequency of harms. By contrast, statins used in secondary
prevention undoubtedly lower the risk of further cardiovascular
events and cut all-cause mortality by about 15%.21 Their adverse
effects are well established. Serious reactions such as significant
rhabdomyolysis are rare, although statins may increase the risk
of diabetes.22 Generic statins are also inexpensive. The maximum
dose of generic atorvastatin costs less than £1 (€1; $1.2) a week
in England; PCSK9 inhibitors cost 100 times more.
The PCSK9 inhibitors are a seductive example of 21st century
medicine, using monoclonal antibody technology to exploit a
fascinating genetic observation and careful physiological
analysis. There are other inhibitors in the pipeline, including
inclisiran,23 a small interfering RNA that reduced PCSK9
synthesis and LDL cholesterol concentration in volunteers
without hypercholesterolaemia in a phase I trial.
Evolocumab and alirocumab, however, have been licensed on
the basis of a surrogate biochemical measure, rather than
clinically relevant outcomes. For now, NICE is right to limit
the use of these expensive medicines to highly selected
subgroups. Their clinical efficacy and long term safety remain
uncertain.
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